Butler holds firm on semaglutide compounding ban

Government says 'no', to lifting ban on compounding glucagon-like peptide-1 receptor agonists (GLP-1 RAs)  Risks associated with compounded GLP-1 RAs outweigh the benefits of improved access to the medication, Mark Butler the Minister for Health and Aged Care says.  Responding to a petition calling on the government to establish an approval mechanism for compounded semaglutide